ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma
Successful implementation of biosimilars through effective communication
Continuous treatment versus fixed duration therapy: Using real-world evidence to guide treatment paradigms for multiple myeloma
Appraising an NTRK testing algorithm: When, what, how
Optimising regorafenib dosing in mCRC
Evaluating treatment options for acute myeloid leukaemia
Cancer control in Africa - Special Issue
Radiotherapy for liver cancer, and neoadjuvant therapy for rectal cancer
An overview of the latest advances in gastric cancer
Supportive care in cancer treatment
Treating HER2-mutant advanced biliary tract cancer with neratinib